InSilicoTrials

Hyper-accelerate Drug Development



Our MISSION is to revolutionize drug development with the power of *in silico* technology

Today’s Problem

Development of new products in Pharma is challenging



$2.6BN

Average investment to develop a new drug

12 Years

Average time to get drugs over the finish line

5%

Average percentage of novel drugs approved by regulators

ROI

1.2 %, 2022 ROI on Pharma R&D spending, lowest in last 13 years

FDA and EU Parliament are endorsing strong innovation in clinical trials.

Solution

Cutting-edge AI and Modeling & Simulation platform
to predict clinical trial outcomes



InSilicoTrials Platform features models from world-renowned scientific institutions and regulatory bodies such as the FDA, fully aligned with guidelines from both the FDA and EMA.

Engagement in Regulatory Science

We are co-editor of the book *Toward Good Simulation Practice*

+130
researchers from university and industry

Boston Scientific · Medtronic · Johnson & Johnson

&

+13
FDA members

FDA U.S. FOOD & DRUG ADMINISTRATION



"The implementation of Good Simulation Practice is seen as a key factor in ensuring the sustained success of M&S in the healthcare field."

Pras Pathmanathan
Office of Science and Engineering Laboratories | Center for Devices and Radiological Health | U.S. Food and Drug Administration

Value Proposition

Nonclinical and Clinical Trials Simulations



Benefits

AI-generated **prognostic digital twins** for clinical trials simulation **in MS**

Multiple sclerosis disease progression and treatment effect prediction on more than 3.000 MS Virtual Patients in just 1 day of simulation time

Estimated Savings:
€20Mil
4 years of clinical trial time

Benefits

Multiple **clinical trials simulations** in **CNS**

Testing the compound in diverse disease progression models in CNS

Client-Identified Advantages

- ✓ De-risk clinical plan with safety simulations
- ✓ Discover new indications and unlock market potential without clinical trial execution costs

Estimated Savings:
€30 Mil
3 years of clinical trial time

Main Collaborations

Strong Experience in Digital Simulation Pharma and MedTech

Luca Emili
CEO & Founder
M.S. in Economics

Serial Entrepreneur,
20+ years track record
in IT and Cybersecurity

Mario Torchia
Chief Operating Officer
M.Eng. in Computer Science

+14 years in healthcare
and M&S. Former Executive
of Dassault Systèmes

Matteo Gazzin
Engineering Manager
M.Eng. in Computer Science

+10 years in numerical
Optimization and simulation
data management

Mark Lovern
Chief Plattform Officer
PhD. Biomathematics

25+ years of experience in the
application of model-informed drug
development (MIDD)

The Team 7 Nationalities | **29 employees** (majority with Ph.D. or MBA)

Advisors

Stefano Bini | Academia
CTO University
of California
San Francisco

UCSF

Guido Rasi | Regulator
Former Executive
Director at EMA
Rome

EUROPEAN MEDICINES AGENCY

Alessandro De Luca | BigPharma
CIO Merck
Darmstadt

MERCK

Michael Eckstut | M&S Platform
Former Senior Vice
President
New Jersey

CERTARA

We are ready for the future of medicine, are you?

Thank you.